The Effectiveness of rTMS in Depressed VA Patients


I'm Interested

Trial ID: NCT01191333


The purpose of this multi-site trial is to determine if repetitive Transcranial Magnetic Stimulation (rTMS) helps people with depression who have not been helped by medications or who have not been helped enough by medications.

Official Title

CSP #556 - The Effectiveness of rTMS in Depressed VA Patients

Stanford Investigator(s)


Inclusion Criteria:

   - Between 18 and 80 years of age

   - Using the Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)
   Disorders (SCID) for DSM-IV-TR (First et al. 2002) patients will be diagnosed Major
   Depressive Disorder (MDD).

   - Have a Hamilton Rating Scale for Depression (HRSD-24) score greater or equal to 20 no
   more than 7 days prior to randomization.

   - Exhibit moderate level of resistance to antidepressant treatment defined, using the
   Antidepressant Treatment History Form (ATHF) (Sackeim et al. 1990), as failure of at
   least two adequate medication trials.

   - Duration of current episode of less than or equal to 10 years.

   - Ability to obtain a Motor Threshold (MT) (should be determined at the end of the
   screening process).

   - Currently under the care of a VA psychiatrist.

   - If on a psychotropic medication regimen, that regimen will be stable for at least 4
   weeks prior to randomization and patient will be willing to remain on a stable regimen
   during the acute treatment phase.

   - Has an adequately stable condition and environment to enable attendance at scheduled
   clinic visits.

   - For female participants, agrees to use one of the following acceptable methods of
   birth control

      - Complete abstinence (not having sexual intercourse with anyone)

      - An oral contraceptive (birth control pills)

      - Norplant

      - Depo-Provera

      - A condom with spermicide

      - A cervical cap with spermicide

      - A diaphragm with spermicide

      - An Intrauterine device

      - Surgical sterilization (having tubes tied)

   - Able to read, verbalize understanding and voluntarily sign the Informed Consent Form
   prior to performance of any study-specific procedures or assessments.

Exclusion Criteria:

   - Pregnant or lactating female (This is an FDA-required exclusion. In the future, if
   rTMS becomes a proven treatment for major depression, its safety in the context of
   pregnancy should be studied separately (Nahas et al. 1999).

   - Unable to be safely withdrawn, at least two-weeks prior to treatment commencement,
   from medications that substantially increase the risk of having seizures. For the
   purpose of this study, those medications are listed in Appendix G (for example,

   - Have a cardiac pacemaker.

   - Have an implanted device (deep brain stimulation) or metal in the brain.

   - Have a cochlear implant.

   - Have a mass lesion, cerebral infarct, increased intracranial pressure, or other active
   central nervous system (CNS) disease, including a seizure disorder.

   - Known current psychosis as determined by DSM-IV or SCID (axis I, psychotic disorder,
   schizophrenia) or a history of a non-mood psychotic disorder.

   - Known current Bipolar I disorder as determined by SCID or a History of Bipolar I

   - Current amnestic disorders, dementia, Blessed Orientation-Memory-Concentration (BOMC)
   greater than 10, delirium, or other cognitive disorders.

   - Current substance abuse (not including caffeine or nicotine) as determined by positive
   toxicology screen, or by history via SCID, within 3 months prior to screening.

   - Patients with an elevated risk of seizure due to traumatic brain injury (TBI).

   - Participation in another concurrent clinical trial.

   - Patients with prior exposure to rTMS.

   - Active current suicidal intent or plan as evidenced by a score of 4 or 5 on the
   suicidal ideation portion of the Columbia Suicide Severity Rating Scale (C-SSRS) or
   the endorsement of an actual attempt, interrupted attempt, or an aborted attempt in
   the past 6 months. All patients will be required to establish a written safety plan
   involving their primary psychiatrist and the treatment team before entering the
   clinical trial (See Section X.B.8).

   - Unstable cardiac disease or recent (< 3 months previous) myocardial infarction.

   - Patient refuses to sign consent for participation in the study.


device: rTMS

device: Sham Device


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Rebecca Lenox